COSENTYX 150 MG PRE-FILLED PEN

4,791.00 EGP

Cosentyx  (Secukinumab) is a human IgG1 monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin 17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses and plays a key role in the pathogenesis of plaque psoriasis.

If you purchase this product you will earn 479 Points worth of 4.79 EGP!

COSENTYX 150 MG PRE-FILLED PEN

Cosentyx is a human IgG1 monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin 17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses and plays a key role in the pathogenesis of plaque psoriasis.

Active Ingredient Of Cosentyx

Secukinumab

Therapeutic indications

  • Adult plaque psoriasis

Doctors prescribe Cosentyx for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

  • Paediatric plaque psoriasis

Doctors prescribe Cosentyx for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

  • Psoriatic arthritis

To start with, cosentyx, alone or in combination with methotrexate (MTX), doctors prescribe Cosentyx for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

  • Axial spondyloarthritis

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis). Doctors prescribe Cosentyx for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

  • Non-radiographic axial spondyloarthritis

Doctors prescribe Cosentyx for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs).

 

Mechanism of action

At the beginning, Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.

Method of Administration

You can must take it by subcutaneous route of administration.

 

cosentyx
cosentyx
Side effects
  • Infection: Infection (29% to 48%; serious infection: ≤1%)
  • Respiratory: Nasopharyngitis (11% to 12%)
  • Dermatologic: Urticaria (≤1%)
  • Endocrine & metabolic: Hypercholesterolemia (≥2%)
  • Gastrointestinal: Diarrhea (3% to 4%), inflammatory bowel disease (≤1%; Crohn’s disease, exacerbation of Crohn’s disease, exacerbation of ulcerative colitis, ulcerative colitis: <1%)
  • Nervous system: Headache (≥2%)
  • Respiratory: Pharyngitis (1%), rhinitis (1%), rhinorrhea (≤1%), upper respiratory tract infection (3%)

 

Watch Video

Reviews

There are no reviews yet.

Be the first to review “COSENTYX 150 MG PRE-FILLED PEN”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat